<DOC>
	<DOCNO>NCT01639911</DOCNO>
	<brief_summary>This phase I dose escalation study evaluate alisertib , Aurora A kinase inhibitor , give combination selective vascular endothelial growth factor receptor ( VEGFR ) inhibitor pazopanib patient advance , previously treat non-hematologic solid tumor .</brief_summary>
	<brief_title>MLN8237 Pazopanib Combination Solid Tumors</brief_title>
	<detailed_description>Alisertib take orally twice day 1st 7 day 21 day cycle . Pazopanib take orally day continuously begin day 10 cycle 1 allow alisertib pharmacokinetics ( PKs ) . Treatment continue disease progression , unacceptable toxicity , patient refusal . PKs do patient association last dose alisertib cycle 1 2 .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Urogenital Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Thoracic Neoplasms</mesh_term>
	<criteria>Diagnosis advance nonhematologic solid tumor malignancy failed/become intolerant standard therapy Measurable disease per RECIST Age ≥ 18 year ECOG PS 02 Prior systemic chemotherapy , immunotherapy , biological therapy allow ; however prior use study drug combination allow . Must recover reversible effect previous anticancer tx Adequate organ function within 14 day study registration Patient must able take oral medication maintain fast require 2 hr 2 hr alisertib admin . Subjects agree use contraception , need Untreated symptomatic CNS metastases Radiation therapy 25 % bone marrow . Whole pelvic radiation exclude . Prior allogeneic BMT &gt; = Grade 2 peripheral neuropathy within 14 day enrollment Known history uncontrolled sleep apnea &amp; condition could result excessive daytime sleepiness Requirement constant admin . proton pump inhibitor , H2 antagonist , pancreatic enzyme . Systemic infection require IV antibiotic within 14 day precede 1st dose study drug , severe infection . MI within 6 mo . prior enrollment NYHA Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , CVA , pulmonary embolism untreated DVT evidence acute ischemia active conduction system abnormality ECG ( e.g. , repeat QTc interval &gt; 450 msec ) Pregnant breastfeeding . Patient receive investigational drug 14 day Serious medical/psychiatric illness opinion PI would likely interfere participation Diagnosed treat another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy . Treatment clinically significant enzyme inducer , enzyme induce antiepileptic drug phenytoin , carbamazepine phenobarbital , rifampin , rifabutin , rifapentine St. John 's wort within 14 day Known history HIV infection , hepatitis B , hepatitis C. Recent ( within 6 month ) arterial thromboembolic event , include TIA , CVA , unstable angina , MI . Pts . clinically significant PAD ineligible . History thrombotic hemorrhagic disorder , receive chronic daily treatment ASA ( &gt; 325 mg/day ) NSAIDs know inhibit platelet function . Treatment dipyridamole ( persantine ) , ticlopidine ( Ticlid ) , clopidogrel ( Plavix ) and/or cilostazol ( Pletal ) . History abdominal fistula , GI perforation , intraabdominal abscess within 28 day prior begin study treatment Clinically significant GI abnormality may affect absorption IP include , limited : Ongoing nausea vomit severity &gt; grade 1 diarrhea Malabsorption syndrome Major resection stomach small bowel Inability swallow oral medication inability take nothing mouth except water prescribe medication 2 hr 2 hr dose alisertib . Poorly control HTN [ SBP ≥140 mmHg DBP ≥ 90mmHg ] . Prior major surgery/trauma within 28 day presence nonhealing wound , fracture , ulcer Evidence active bleeding Known endobronchial lesion involvement large pulmonary vessel tumor centrally locate pulmonary cavitating lesion Hemoptysis within 6 week Unable unwilling D/C use prohibit medication least 14 day prior 1st dose study drug duration study Known immediate delay hypersensitivity reaction idiosyncrasy pazopanib alisertib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>malignant solid tumor</keyword>
	<keyword>advanced non-hematologic</keyword>
</DOC>